Interleukin (IL)
The picture emerging from these studies, as well as from a series of somewhat controversial in vitro data concerning the effects of IL-33 on human and mouse bone cells (Table 1 ) (4-6), is thus that IL-33 decreases osteoclast differentiation by acting at early stages on bone marrow precursors to prevent commitment to the osteoclast lineage, and to favor emergence of alternative myeloid cell fates instead, such as AAMs in particular (Fig. 1) . In agreement with this hypothesis, several studies have failed to detect any effect, negative or positive, of IL-33 on osteoclast + peripheral blood monocytes, which represent a later stage of monocyte differentiation (2;5;6) ( Fig. 1) . At odds with these observations, however, Mun and colleagues (4) reported a strong RANKL-independent stimulatory effect of IL-33 on differentiation of CD14 + monocytes into osteoclasts. While the reasons for this discrepancy remain unclear, they might relate to differences in purity of cell preparations or in culture and assay conditions used, as discussed in (6). Fig. 1 . Inhibitory effect of IL-33 on osteoclast differentiation. IL-33 acts at early stages on bone marrow myeloid progenitors to prevent commitment to the osteoclast lineage, and to favor emergence of alternative cell fates, such as M2 macrophages, eosinophils or basophils. Recent data suggest that this effect is indirect and mediated by the production of anti-osteoclastogenic cytokines, such as GM-CSF, IL-4, IL-10 and IL-13, by various cell types, which include mature macrophages, T cells or osteoblasts.
Another twist to this interesting story is that the effect of IL-33 on bone marrow macrophage precursors to limit commitment to the osteoclast lineage is probably indirect, and mediated by the production of a combination of anti-osteoclastogenic factors such as GM-CSF, IL-4, IL-13 and IL-10, which together optimally inhibit osteoclast differentiation (6) . While production of such factors has been observed in cultures of purified mouse CD11b + bone marrow cells, and thus in absence of bone marrow stromal cells (1;2) , a recent study suggests that it requires the presence of cell types other than the osteoclast precursors themselves, including, for instance, mature macrophages, T cells or osteoblasts (6) (Fig.  1) .
Another open question lies with the influence of IL-33 on bone formation. Reported in vitro findings disagree concerning effects of IL-33 on human and mouse osteoblast cultures, and in particular concerning a potential stimulation of matrix mineralization (1;5;6) . Furthermore, in vivo data indicate normal bone formation in ST2 KO mice (1) , such that the relevance of reported in vitro effects of IL-33 on osteoblasts remains to be established.
Finally, while Zaiss et al. report a protective effect of IL-33 on bone loss in the hTNFtg model, IL-33 was previously shown to be a potent pro-inflammatory mediator in other models of arthritis, including collagen-, antigen-and K/BxN serum transfer-induced arthritis (7) (8) (9) (10) . In these models, IL-33 contributes to increasing bone and cartilage erosion scores, although this effect may be at least in part indirect and mediated by proinflammatory effects of IL-33 and induction of RANKL expression in the joint (8) . This dual role of IL-33 in the control of bone turnover is reminiscent of similar effects reported for IL-1. Indeed, exposure to IL-1β prior to, or together with, RANKL, was reported to suppress osteoclastogenesis in human CD14 + monocytes and rheumatoid arthritis synovial fluid macrophages (11) . To the contrary, there is substantial evidence to indicate that, in vivo, IL-1 acts primarily as a pro-resorptive cytokine in many physiological and pathological situations. As for IL-1, suppressive functions of IL-33 on bone resorption may thus be contextdependent and biologically relevant only in specific circumstances. This important issue clearly warrants further study. In summary, two recent papers demonstrate an inhibitory effect of IL-33 on bone resorption by a unique mechanism. While controversial findings have been reported concerning the effects of IL-33 on osteoclast and osteoblast differentiation and activity in vitro, which to some extent may reflect differences in experimental systems and cell populations used, these studies now provide an in vivo context for further definition of the role of IL-33 in bone biology and of potential therapeutic opportunities involving this cytokine.
